Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.

@article{Wen2014TargetingJS,
  title={Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.},
  author={Wei Wen and Wei Liang and Jun Wu and Claudia M. Kowolik and R. E. Buettner and Anna Scuto and Meng-Yin Hsieh and Hao Hong and Christine E Brown and Stephen J. Forman and David Andrew Horne and Robert Joseph Morgan and Mark T. Wakabayashi and Thanh H. Dellinger and Ernest Soyoung Han and John H. Yim and Richard Jove},
  journal={Molecular cancer therapeutics},
  year={2014},
  volume={13 12},
  pages={
          3037-48
        }
}
JAK/STAT3 is one of the major signaling pathways that is aberrantly activated in ovarian cancer and associated with tumor progression and poor prognosis in patients with ovarian cancer. In this study, we evaluated the therapeutic potential of targeting JAK/STAT3 signaling in ovarian cancer using a peritoneal dissemination mouse model. We developed this mouse model by injecting a metastatic human ovarian cancer cell line, SKOV3-M-Luc, into the peritoneal cavity of immunodeficient mice. This… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer

Song Liu, Junko Matsuzaki, +19 authors Kunle Odunsi
  • Journal for ImmunoTherapy of Cancer
  • 2019

ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of androgen-independent prostate cancer

Lan Zhang, Li‑Jun Xu, +8 authors Y. Shan
  • Molecular medicine reports
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

MicroRNA-340 inhibits the proliferation and invasion of hepatocellular carcinoma cells by targeting JAK1.

  • Biochemical and biophysical research communications
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND